ICU Medical (ICUI) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $596.5 million, up 8.6% year-over-year, with growth across Consumables, Infusion Systems, and Vital Care segments.

• Adjusted EBITDA was $91.3 million, down from $98.1 million last year; adjusted EPS was $1.56, down from $1.88.

• GAAP net loss widened to $21.4 million, or $(0.88) per diluted share, due to higher restructuring and integration costs.

• Gross margin was 34.8%, slightly down from 35.0% last year, but adjusted gross margin improved to 37%.

• Operating cash flow for the first half of 2024 was $127.7 million, with cash and equivalents at $302.6 million at quarter end.

Financial highlights

• Total revenues for the first six months of 2024 were $1.16 billion, up 4.0% year-over-year.

• Adjusted SG&A expense was $117 million; adjusted R&D was $23 million for Q2.

• Operating expenses rose to $199.7 million in Q2 2024, mainly due to higher SG&A and restructuring costs.

• Adjusted EBITDA margin for Q2 2024 was 15.3% of revenue, down from 17.9% in Q2 2023.

• Effective tax rate for Q2 2024 was (10)%, compared to 57% in Q2 2023.

Outlook and guidance

• Full-year adjusted EBITDA guidance raised to $345–$365 million (from $330–$370 million).

• Full-year adjusted EPS guidance raised to $4.95–$5.35 per share (from $4.40–$5.10).

• FY 2024 GAAP net loss guidance improved to $(118)M–$(108)M.

• Capital expenditures for 2024 expected at $85–$100 million, weighted to the second half.

• Liquidity expected to remain strong, with sufficient cash and credit facilities for the next twelve months.